US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M2.
- Target
- Muscarinic acetylcholine receptor M2
- Mechanism
- Muscarinic acetylcholine receptor M3 agonist
biotech · Moderately to Severely Active Ulcerative Colitis · Inflammatory Bowel Diseases · ODTX
Odyssey Therapeutics
Odyssey Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Ramon, USA HQ
3 Employees
Public company Type
ODTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Ramon, USA
- Employees
- 3
- Programs
- 4
- Drugs
- 6
- Patents
- 1
Odyssey Therapeutics pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Odyssey Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Aldehyde dehydrogenase, mitochondrial.
- Target
- Aldehyde dehydrogenase, mitochondrial
- Mechanism
- Aldehyde dehydrogenase inhibitor
-
Development asset linked to Odyssey Therapeutics in public FDA and regional records.
-
Development asset linked to Odyssey Therapeutics in public FDA and regional records.
-
Development asset linked to Odyssey Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Integrin alpha-4/beta-7.
- Target
- Integrin alpha-4/beta-7
- Mechanism
- Integrin alpha-4/beta-7 inhibitor